Research using the most cutting-edge Magnetic Recsonance Imaging (MRI), confirms that pharmaceutical-grade chondroitin sulphate, (CSbBIOACTIVE), significantly reduces the effects of osteoarthritis on the knee.
Osteoarthritis is the most common type, with 27 million people living in the U.S. The condition can lead to the destruction of cartilage and other joints, leading to stiffness, pain, and loss in movement. Cartilage acts as a shock-absorbing and friction reducer by providing a hard, rubbery layer on the joints. The cartilage becomes less elastic and loses its cushioning ability with osteoarthritis. This causes the bones to rub against one another. Cartilage degeneration can cause the joint to become less flexible and affect its shape. In the bone, there may be bone marrow lesion-like bruises that can cause knee pain.
Recently published trial results in an important arthritis journal show that chondroitin Sulphate treatment significantly reduced cartilage losses and bone marrow lesion from osteoarthritis.
Chondroitin, a natural substance found in the body, helps maintain healthy cartilage by absorbing fluids and providing building blocks for new cartilage. Chondroitin could also block enzymes responsible for destroying cartilage.
Recent advancements in MRI technology made it possible for Dr. Jean-Pierre Pelletier (University of Montreal Hospital Research Centre) to measure for the very first time the effects of chondroitin sulfate. This was done by Jean-Pierre Pelletier along with his team. Researchers were able to demonstrate significant improvements in the results of chondroitin-sulfate treatment using the most recent technology.
Six months after treatment, patients had significantly less cartilage loss than those who received placebo. The size of bone marrow tumors was significantly reduced by treatment 12 months later.
“Reducing bone marrow lesions may help lessen some of the pain associated with osteoarthritis,” said Dr. Pelletier. “From these results, we can conclude that chondroitin sulfate is a safe drug that significantly reduces the volume of cartilage loss and slows down the progression of osteoarthritis in the knee.”He noted that “Patients must be provided highly purified pharmaceutical-grade chondroitin sulphate, the one used in this study, as this is the only one that can guarantee such efficacy and specifically, safety results.”
